Heterogeneity and Coexistence of T790M and T790 Wild-Type Resistant Subclones Drive Mixed Response to Third-Generation Epidermal Growth Factor Receptor Inhibitors in Lung Cancer

PURPOSE: Third-generation epidermal growth factor receptor (EGFR) inhibitors like nazartinib are active against EGFR mutation–positive lung cancers with T790M-mediated acquired resistance to initial anti-EGFR treatment, but some patients have mixed responses. METHODS: Multiple serial tumor and liqui...

Πλήρης περιγραφή

Αποθηκεύτηκε σε:
Λεπτομέρειες βιβλιογραφικής εγγραφής
Τόπος έκδοσης:JCO Precis Oncol
Κύριοι συγγραφείς: Piotrowska, Zofia, Hazar-Rethinam, Mehlika, Rizzo, Coleen, Nadres, Brandon, Van Seventer, Emily E., Shahzade, Heather A., Lennes, Inga T., Iafrate, Anthony J., Dias-Santagata, Dora, Leshchiner, Ignaty, Jessop, Nicholas A., Hu, Haichuan, Digumarthy, Subba R., Nagy, Rebecca J., Lanman, Richard B., Moody, Susan, Niederst, Matthew J., Engelman, Jeffrey A., Hata, Aaron N., Corcoran, Ryan B., Sequist, Lecia V.
Μορφή: Artigo
Γλώσσα:Inglês
Έκδοση: American Society of Clinical Oncology 2018
Θέματα:
Original Report
Διαθέσιμο Online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6097183/
https://ncbi.nlm.nih.gov/pubmed/30123863
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00263
Ετικέτες: Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!

Παρόμοια τεκμήρια